The U.S. Food and Drug Administration (FDA) fulfills its mission to protect and advance the public health by overseeing the development and approval of new medical products and ensuring that they are safe and effective for American consumers. When taking into consideration the full range of products the FDA oversees, including not just medical products,…
Significant progress has been made in data collection efforts to support use of real-world evidence (RWE) in regulatory settings; however challenges remain, chiefly with combining, organizing, and analyzing data from various information sources. On July 10th, Friends of Cancer Research (Friends) hosted a meeting to present data from a pilot project assessing the use and…
Friends of Cancer Research Congressional Briefing Safeguarding the Public Health: Enhancing Information About Prescription Drugs Patients and their caregivers need access to high quality information about the prescription drugs they use. While many sources of information exist, none can deliver as strong assurances of reliability and scientific rigor as FDA-approved product labels. Labels are the…
Robust drug development for pediatric cancers is critical to ensuring appropriate access to life-saving drugs and promoting innovation. As such, the FDA Reauthorization Act (FDARA) of 2017 included a provision requiring sponsors to investigate new molecularly targeted cancer drugs and biologics that are determined to be substantially relevant to the growth or progression of pediatric…
November 14, 2017 Disruption In Biopharma The Ritz-Carlton, Washington D.C. 1150 22nd Street, NW On Tuesday, November 14, 2017, Friends of Cancer Research (Friends) and Prevision Policy hosted the third annual BioPharma Congress. This year’s event focused on disruption in biopharma and featured speakers such as former FDA Commissioner Dr. Mark McClellan and former Senate…
Panel 1 Whitepaper – Panel 1 Slides Panel 2 Whitepaper – Panel 2 Slides Panel 3 Whitepaper – Panel 3 Slides This year’s Friends Annual Meeting took place on November 15, 2017. The event began with a keynote by FDA Commissioner Dr. Scott Gottlieb. During his remarks, Dr. Gottlieb reiterated previous commitments for the…
Friends of Cancer Research with Alexandria Real Estate Equities, Inc. Co-Host: A Blueprint for Breakthrough – Charting the Course for Precision Medicine Click HERE to access the finalized meeting whitepaper. On Wednesday, September 13, 2017, Friends of Cancer Research (Friends) with Alexandria Real Estate Equities Inc. co-hosted the 6th annual Blueprint for Breakthroughs forum. This…
October 4, 2017 The Hay-Adams 800 16th St NW, Washington, DC 20006 On October 4, 2017, Friends of Cancer Research (Friends) hosted the 21st Annual Cancer Leadership Awards Reception. The yearly event brings together leaders in government, advocacy, industry, and science to celebrate partnerships and innovations that benefit patients. To mark the five-year anniversary of…
Friends of Cancer Research Vice President – Public Affairs, Ryan Hohman, shares why he is passionate about the Friends mission of bringing life-saving treatments to patients in the fastest and safest way possible in the latest installment of “My Story.” From a young age, Ryan has been witness to how cancer impacts families and saw what he…
In his first speech to Congress last February, President Trump revived a common misconception about drug regulation. The president’s comments reflect a perennial critique of the FDA, that the agency’s drug regulations impede timely access to new medicines. A few years ago, Friends of Cancer Research (Friends) explored whether these claims were true about cancer…
